Jonathan Young, the Chief Operating Officer of Akero Therapeutics, Inc. (NASDAQ:AKRO), a biotech company with a market capitalization of $2 billion, recently sold 2,503 shares of the company's common stock. The stock has shown strong momentum with a 24% gain year-to-date, according to InvestingPro data. The shares were sold at a weighted-average price of $30.79 per share, amounting to a total transaction value of $77,067. This sale was conducted to cover tax withholding obligations related to the vesting of restricted stock units, as part of the company's "sell-to-cover" policy. Following the transaction, Young holds 203,783 shares directly. Additionally, shares are held in irrevocable trusts for his children, with his spouse serving as trustee. InvestingPro analysis shows the company maintains a strong financial health score, with liquid assets exceeding short-term obligations. Subscribers can access 8 additional key insights about AKRO's financial position and market performance.
In other recent news, Keros Therapeutics has paused dosing in certain arms of its Phase 2 TROPOS Trial following a safety review that identified unexpected cases of pericardial effusion. The company is currently collaborating with trial investigators, the Food and Drug Administration, and other regulatory authorities to resolve the issue. Despite the halt in dosing, Keros will continue to collect safety and efficacy data for all groups involved in the trial and expects to present topline data in the second quarter of 2025.
On the other hand, Akero Therapeutics has been making significant strides in the healthcare sector. The company's HARMONY study has revealed positive clinical outcomes from its Phase 2b study of efruxifermin (EFX) for treating metabolic dysfunction-associated steatohepatitis (MASH). The data showed that after 96 weeks of EFX treatment, over 40% of participants exhibited regression of liver fibrosis.
Further, Akero has initiated all three Phase 3 trials of EFX, marking a significant step in its journey. The SYNCHRONY Outcomes trial, which aims to evaluate EFX's efficacy in patients with fibrosis stage 4, has already dosed its first patient.
In light of these developments, analysts from Citi and H.C. Wainwright have expressed their positive outlooks on Akero's stock. Citi initiated coverage with a Buy rating based on the potential of efruxifermin to be a leading therapy for MASH, while H.C. Wainwright maintained its Buy rating as Akero progresses with its Phase 3 trial for MASH patients with compensated cirrhosis.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.